S. Mohana Lakshmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. Mohana Lakshmi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Shivangi Sharma
Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, Madhya Pradesh, 474005, India
2 shared publications - C.K. Ashok Kumar1 shared publication
- Gouranga Dutta
Department of Pharmaceutics, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur 603203, Tamil Nadu, India
1 shared publication - Haleema Shahin D.H.
Department of Pharmacology, Yenepoya Pharmacy College and Research Centre Yenepoya (Deemed to be) University Mangalore India
1 shared publication Mishika Singh
Department of Pharmacognosy, Amity School of Pharmacy, Amity University Madhya Pradesh, Maharajpura Dang, Gwalior, 474005, India
1 shared publication- Murugesan Vanangamudi
Institute of Pharmaceutical Research, GLA University, Mathura, UttarPradesh, 281406, India
1 shared publication
Latest Publications
- 21 October 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (8) , e70718
Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research
Microglia are the immune cells resident in the central nervous system (CNS) and are involved in CNS homeostasis and in responses to injury and disease. Microglia, upon activation, become pro‐inflammatory (M1) or anti‐inflammatory (M2), with M1 being neurotoxic and M2 participating in tissue repair. The activation of microglia in neuroinflammation and pain hypersensitivity is important in the neurodegenerative disorders such as Parkinson's (PD) and Alzheimer's disease ( AD ). Recent investigations have identified GLP‐1 receptor agonists (GLP‐1 RAs) as potent pharmacological agents that can regulate the activity of the microglia. GLP‐1RA attaches to the GLP‐1 receptor found on the microglia to cause a phenotypic shift to the anti‐inflammatory M2 form, which, in turn, reduces neuroinflammation and increases neuronal protection. Experimental evidence shows that GLP‐1 RAs are effective at reducing hypersensitivity to pain, improving cognitive performance, and attenuating inflammatory effects in preclinical models of AD , PD, and multiple sclerosis (MS). All these facts suggest that GLP‐1 RAs are a significant treatment option in chronic pain and neurodegenerative disease management, as they can change microglial polarization and suppress neuroinflammation.
- 21 October 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (8) , e70718
Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research
Microglia are the immune cells resident in the central nervous system (CNS) and are involved in CNS homeostasis and in responses to injury and disease. Microglia, upon activation, become pro‐inflammatory (M1) or anti‐inflammatory (M2), with M1 being neurotoxic and M2 participating in tissue repair. The activation of microglia in neuroinflammation and pain hypersensitivity is important in the neurodegenerative disorders such as Parkinson's (PD) and Alzheimer's disease ( AD ). Recent investigations have identified GLP‐1 receptor agonists (GLP‐1 RAs) as potent pharmacological agents that can regulate the activity of the microglia. GLP‐1RA attaches to the GLP‐1 receptor found on the microglia to cause a phenotypic shift to the anti‐inflammatory M2 form, which, in turn, reduces neuroinflammation and increases neuronal protection. Experimental evidence shows that GLP‐1 RAs are effective at reducing hypersensitivity to pain, improving cognitive performance, and attenuating inflammatory effects in preclinical models of AD , PD, and multiple sclerosis (MS). All these facts suggest that GLP‐1 RAs are a significant treatment option in chronic pain and neurodegenerative disease management, as they can change microglial polarization and suppress neuroinflammation.
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Current Nanomaterials
- Vol. 10 (3) , 256-272
Conducting Polymer Nanofibers and Nanotubes as a Potential Nanotechnology: Current Status and Future Directions
Conducting polymers (CPs) have garnered a lot of attention in recent years due to the financial significance they have, the high environmental stability they exhibit, the electrical conductivity they possess, and the beneficial mechanical, optical, and electronic qualities they possess. Conducting polymers have a wide range of uses, including but not limited to the following: diodes, transistors, artificial nerves, aviation construction, conducting adhesives, electromagnetic shielding against electromagnetic interference (EMI), and electrostatic materials. These nanofibers and nanotubes have a wide range of potential applications, including but not limited to: actuators, drug delivery, brain interfaces, nanodiodes, field emission and electrochromic displays, supercapacitors and energy storage, sensors, nanodiodes, field effect transistors, drug delivery, and protein purification. The purpose of this review is to discuss a few of these applications as well as their possible applications in the future.
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Current Nanomaterials
- Vol. 10 (3) , 256-272
Conducting Polymer Nanofibers and Nanotubes as a Potential Nanotechnology: Current Status and Future Directions
Conducting polymers (CPs) have garnered a lot of attention in recent years due to the financial significance they have, the high environmental stability they exhibit, the electrical conductivity they possess, and the beneficial mechanical, optical, and electronic qualities they possess. Conducting polymers have a wide range of uses, including but not limited to the following: diodes, transistors, artificial nerves, aviation construction, conducting adhesives, electromagnetic shielding against electromagnetic interference (EMI), and electrostatic materials. These nanofibers and nanotubes have a wide range of potential applications, including but not limited to: actuators, drug delivery, brain interfaces, nanodiodes, field emission and electrochromic displays, supercapacitors and energy storage, sensors, nanodiodes, field effect transistors, drug delivery, and protein purification. The purpose of this review is to discuss a few of these applications as well as their possible applications in the future.
- 1 November 2024
- Published by Taylor & Francis
- p. 160-178
Lipid-Based Nanoparticles
Lipid-based nanocarriers have great potential to solubilize, encapsulate, and deliver active molecules in a programmed pattern to achieve desired bioavailability and avoid side effects. Nanocarrier-based delivery of phytochemicals exhibits enhanced aqueous solubility and bioavailability, specific tumor cell/tissue targeting, improved cellular uptake, reduced doses of phytochemicals, and steady-state therapeutic levels of the phytochemicals over an extended period of time while minimizing side effects and toxicity. In addition to that, it also shows excellent blood stability, multifunctional design of nanocarriers, and improvement in anticancer activities. Nanostructured lipid carriers (NLCs) provide the advantage of a controlled release system and have been increasingly developed as drug carriers in cancer treatments. PEG-conjugated NLCs escape from the capture of RES to circulate longer than conventional NLCs. NLCs are a second generation of lipid nanoparticles that consists of a mixture of solid and liquid lipids to create an imperfection on the crystal lattice, accommodating high drug load and enhanced penetration.
- 1 November 2024
- Published by Taylor & Francis
- p. 160-178
Lipid-Based Nanoparticles
Lipid-based nanocarriers have great potential to solubilize, encapsulate, and deliver active molecules in a programmed pattern to achieve desired bioavailability and avoid side effects. Nanocarrier-based delivery of phytochemicals exhibits enhanced aqueous solubility and bioavailability, specific tumor cell/tissue targeting, improved cellular uptake, reduced doses of phytochemicals, and steady-state therapeutic levels of the phytochemicals over an extended period of time while minimizing side effects and toxicity. In addition to that, it also shows excellent blood stability, multifunctional design of nanocarriers, and improvement in anticancer activities. Nanostructured lipid carriers (NLCs) provide the advantage of a controlled release system and have been increasingly developed as drug carriers in cancer treatments. PEG-conjugated NLCs escape from the capture of RES to circulate longer than conventional NLCs. NLCs are a second generation of lipid nanoparticles that consists of a mixture of solid and liquid lipids to create an imperfection on the crystal lattice, accommodating high drug load and enhanced penetration.
- 19 August 2024
- Published by Bentham Science Publishers Ltd. in Clinical Cancer Drugs
- Vol. 10, 1-23
Withdrawal: The Biological Effects of Phytochemicals in Cancer: A Review of the Literature
The article has been withdrawn at the request of the author of the journal Clinical Cancer Drugs.Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php.BENTHAM SCIENCE DISCLAIMER:It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneouslysubmitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewheremust be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submittingthe article for publication the authors agree that the publishers have the legal right to take appropriate action against theauthors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyrightof their article is transferred to the publishers if and when the article is accepted for publication.
- 19 August 2024
- Published by Bentham Science Publishers Ltd. in Clinical Cancer Drugs
- Vol. 10, 1-23
Withdrawal: The Biological Effects of Phytochemicals in Cancer: A Review of the Literature
The article has been withdrawn at the request of the author of the journal Clinical Cancer Drugs.Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php.BENTHAM SCIENCE DISCLAIMER:It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneouslysubmitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewheremust be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submittingthe article for publication the authors agree that the publishers have the legal right to take appropriate action against theauthors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyrightof their article is transferred to the publishers if and when the article is accepted for publication.